Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Mike Laffan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK. Hauptthemen laut MEDLINE: von Willebrand Diseases, von Willebrand Factor, Health Resources, Patient Acceptance of Health Care. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda UK Limited.
Abstract (Originalsprache)
Objectives
We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) receiving recombinant von Willebrand factor (rVWF) in surgical settings in the United Kingdom.
Methods
Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the prevention/treatment of surgery‐related bleeds, or the on‐demand treatment of spontaneous/traumatic bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD‐related HCRU data associated with the prevention/treatment of surgery‐related bleeds were collected at first (index) event, for 12 months pre‐index and 3–12 months post‐index.
Results
Twenty patients (55.0% female, 90.0% White/Caucasian, mean age 56.7 years) received rVWF to prevent/treat surgery‐related bleeds at index: normal haemostasis following abnormal bleeding was achieved for all applicable bleeds with limited requirement for additional treatments. Only four patients (all VWD type 2) received exogenous factor VIII in addition to rVWF at index. There were no treatment switches and no likely treatment‐related complications. Physician‐rated treatment satisfaction was ‘excellent’ (36.7%) or ‘good’ (63.3%) for all rVWF‐treated surgery‐related bleeds ( n = 30).
Conclusions
Results support the effectiveness and safety profile of rVWF in a surgical setting in adults with VWD, supplementing the growing body of evidence for rVWF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK.
- Takeda UK Ltd., London, UK.
- HCD Economics, Knutsford, UK.
ORCID-Profile: Oliver Heard
Förderung
- Takeda UK Limited
Zitieren
APA
Laffan, M., Howitt, H., Jones, C., Brighton, S., Willock, R., Sanigorska, A., & Heard, O. (2026). Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom. European Journal of Haematology. https://doi.org/10.1111/ejh.70033
Vancouver
Laffan M, Howitt H, Jones C, Brighton S, Willock R, Sanigorska A, et al. Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom. European Journal of Haematology. 2026. doi:10.1111/ejh.70033
BibTeX
@article{Laffan2026,
author = {Laffan, Mike and Howitt, Heena and Jones, Cheryl and Brighton, Sarah and Willock, Rosa and Sanigorska, Anna and Heard, Oliver},
title = {Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70033}
}
EUVIMED